These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 30553002

  • 1. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.
    Int J Pharm; 2019 Feb 10; 556():172-180. PubMed ID: 30553002
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jul 10; 32(7):2205-16. PubMed ID: 25563977
    [Abstract] [Full Text] [Related]

  • 4. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
    van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.
    Mol Pharm; 2018 Nov 05; 15(11):5124-5134. PubMed ID: 30247919
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.
    Mol Pharm; 2019 Sep 03; 16(9):3842-3852. PubMed ID: 31329454
    [Abstract] [Full Text] [Related]

  • 7. The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib.
    Martínez-Chávez A, Broeders J, Lebre MC, Tibben MT, Rosing H, Beijnen JH, Schinkel AH.
    Eur J Pharm Sci; 2021 Apr 01; 159():105740. PubMed ID: 33524505
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib.
    Li W, Sparidans RW, Martins MLF, El-Lari M, Lebre MC, van Tellingen O, Beijnen JH, Schinkel AH.
    Mol Cancer Ther; 2021 Jun 01; 20(6):1173-1182. PubMed ID: 33785654
    [Abstract] [Full Text] [Related]

  • 10. Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.
    Wang J, Bruin MAC, Gan C, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.
    Int J Pharm; 2020 May 15; 581():119277. PubMed ID: 32234426
    [Abstract] [Full Text] [Related]

  • 11. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
    Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2018 Mar 15; 129():414-423. PubMed ID: 29155017
    [Abstract] [Full Text] [Related]

  • 12. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
    van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2017 Jun 15; 120():43-50. PubMed ID: 28288939
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jan 15; 32(1):37-46. PubMed ID: 24962512
    [Abstract] [Full Text] [Related]

  • 15. ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.
    Martínez-Chávez A, Loos NHC, Lebre MC, Tibben MM, Rosing H, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2022 Apr 15; 178():105954. PubMed ID: 34700018
    [Abstract] [Full Text] [Related]

  • 16. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
    van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2019 Aug 15; 146():104297. PubMed ID: 31175939
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Pharm; 2017 Oct 02; 14(10):3258-3268. PubMed ID: 28880088
    [Abstract] [Full Text] [Related]

  • 20. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
    Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2015 Dec 02; 102():200-7. PubMed ID: 26361725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.